MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $15.28 Million Holdings in CVS Health Co. (NYSE:CVS)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of CVS Health Co. (NYSE:CVS) by 34.2% during the fourth quarter, Holdings Channel reports. The fund owned 340,269 shares of the pharmacy operator’s stock after acquiring an additional 86,715 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in CVS Health were worth $15,275,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Whitebox Advisors LLC acquired a new stake in shares of CVS Health during the fourth quarter valued at approximately $249,000. Hall Laurie J Trustee grew its position in CVS Health by 25,484.4% during the fourth quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator’s stock valued at $517,000 after purchasing an additional 11,468 shares in the last quarter. B&D White Capital Company LLC purchased a new position in CVS Health during the fourth quarter valued at approximately $417,000. Fairfax Financial Holdings Ltd. Can purchased a new position in CVS Health during the fourth quarter valued at approximately $121,742,000. Finally, Seizert Capital Partners LLC grew its position in CVS Health by 22.8% during the fourth quarter. Seizert Capital Partners LLC now owns 569,527 shares of the pharmacy operator’s stock valued at $25,566,000 after purchasing an additional 105,708 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

NYSE:CVS opened at $60.42 on Friday. The stock has a market cap of $76.43 billion, a P/E ratio of 16.51, a PEG ratio of 0.98 and a beta of 0.60. CVS Health Co. has a one year low of $43.56 and a one year high of $72.51. The company has a fifty day moving average price of $66.62 and a 200 day moving average price of $59.16. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60.

CVS Health (NYSE:CVS) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. The firm had revenue of $94.59 billion during the quarter, compared to analysts’ expectations of $93.07 billion. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.31 EPS. Analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.40%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health’s dividend payout ratio is 63.48%.

Insider Activity

In other news, SVP James David Clark sold 7,513 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the sale, the senior vice president now owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. This represents a 47.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael F. Mahoney bought 30,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was purchased at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares in the company, valued at $2,625,045.20. The trade was a 320.65% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.22% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on CVS shares. Wolfe Research boosted their price objective on shares of CVS Health from 67.00 to 70.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Truist Financial boosted their price objective on shares of CVS Health from $82.00 to $84.00 and gave the company a “buy” rating in a research report on Monday. Argus set a $77.00 price objective on shares of CVS Health in a research report on Tuesday, February 18th. JPMorgan Chase & Co. boosted their target price on shares of CVS Health from $80.00 to $81.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 18th. Finally, Leerink Partners raised shares of CVS Health from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $55.00 to $75.00 in a research report on Thursday, February 13th. Three analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and an average target price of $74.94.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.